论文部分内容阅读
目的探讨老年哮喘与慢性阻塞性肺疾病(COPD)患者采用布地奈德联合复方异丙托溴铵溶液治疗的临床疗效及炎症细胞因子情况。方法选取2016年4月至2017年4月沈阳市第四人民医院收治的老年哮喘与COPD患者110例为研究对象,按治疗方法不同分为对照组和研究组,每组55例。对照组患者行单纯布地奈德治疗,研究组患者联合复方异丙托溴铵溶液治疗,比较两组患者的临床疗效及炎症细胞因子情况。结果研究组患者的总有效率为96.4%,高于对照组的80.0%,差异有统计学意义(P<0.05);研究组患者的白细胞介素-8(IL-8)、C反应蛋白、第一秒用力呼气量、最大呼气流速均优于对照组,差异均有统计学意义(均P<0.05)。结论老年哮喘与COPD患者行布地奈德联合复方异丙托溴铵溶液治疗能够改善其临床症状,减轻炎症反应,且能改善其肺功能。
Objective To investigate the clinical efficacy and inflammatory cytokines in patients with senile asthma and chronic obstructive pulmonary disease (COPD) treated with budesonide combined with ipratropium bromide solution. Methods A total of 110 cases of senile asthma and COPD were enrolled in the Fourth People’s Hospital of Shenyang City from April 2016 to April 2017. The subjects were divided into control group and study group with 55 cases in each group. Patients in the control group were treated with simple budesonide. Patients in the study group were treated with ipratropium bromide solution, and the clinical efficacy and inflammatory cytokines were compared between the two groups. Results The total effective rate in study group was 96.4%, which was higher than that in control group (80.0%, P <0.05). The levels of IL-8, C-reactive protein, The first second forced expiratory volume, maximum expiratory flow rate were better than the control group, the differences were statistically significant (P <0.05). Conclusion The combination of budesonide and ipratropium bromide in elderly patients with asthma and COPD can improve its clinical symptoms, reduce the inflammatory reaction and improve its pulmonary function.